title: Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort.
abstract: In APS vascular patients, thrombotic recurrences are more frequent than in non-APS thrombotic patients. To better define this clinical setting, a systematic review of the literature after 1999 was performed: 8 cohort studies (including the recent APS Piedmont Cohort) and 6 intervention studies were selected and evaluated. Thrombotic recurrences, bleeding events, therapeutic strategies, antiphospholipid (aPL) profile, inherited and acquired risk factors (when present) were calculated and compared. Emerging risk factors for thrombotic recurrences include withdrawal of oral anticoagulant therapy (OAT), high intensity OAT (INR range 3-4), aPL profile (triple positivity, Miyakis types 1 and 2a profiles) and association with inherited or acquired pro-thrombotic risk factors. Moreover, there are evidences that high risk (mainly for aPL profile) APS vascular patients have a high recurrence rate in spite of correct OAT treatment. Clinical trials in this clinical setting are needed.
authors.affiliation: Haematology and Thrombosis Unit, Department of Rare, Immunologic, Hematologic Diseases and Transfusion Medicine, Giovanni Bosco Hospital, Turin, Italy. bazzmar@yahoo.com
authors.forename: M
authors.initials: M
authors.lastname: Bazzan
authors.forename: A
authors.initials: A
authors.lastname: Vaccarino
authors.forename: S
authors.initials: S
authors.lastname: Stella
authors.forename: M T
authors.initials: MT
authors.lastname: Bertero
authors.forename: R
authors.initials: R
authors.lastname: Carignola
authors.forename: B
authors.initials: B
authors.lastname: Montaruli
authors.forename: D
authors.initials: D
authors.lastname: Roccatello
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000628:therapy; D015331:Cohort Studies; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D012307:Risk Factors
chemical_list: D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants